<DOC>
	<DOC>NCT00047827</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and effectiveness of micafungin in combination with AmBisome as first-line therapy in the treatment of invasive aspergillosis.</brief_summary>
	<brief_title>Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis</brief_title>
	<detailed_description />
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Inclusion Criteria Have proven or probable systemic infection with Aspergillus species and have received no more than 96 hours of prior therapeutic doses of systemic antifungal therapy Exclusion Criteria Has abnormal liver test parameters, e.g., AST or ALT &gt; 10 times upper limit of normal Has allergic bronchopulmonary aspergillosis, aspergillomas, or with sinus aspergillosis or external otitis who do not have evidence of tissue invasion Has life expectancy of less than five days</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Aspergillus</keyword>
	<keyword>Aspergillosis</keyword>
	<keyword>Anti-Fungal</keyword>
	<keyword>AmBisome</keyword>
	<keyword>Micafungin</keyword>
</DOC>